EP3323817A1 - Dérivés d'aniline pyrimidine et leurs utilisations - Google Patents

Dérivés d'aniline pyrimidine et leurs utilisations Download PDF

Info

Publication number
EP3323817A1
EP3323817A1 EP16823908.5A EP16823908A EP3323817A1 EP 3323817 A1 EP3323817 A1 EP 3323817A1 EP 16823908 A EP16823908 A EP 16823908A EP 3323817 A1 EP3323817 A1 EP 3323817A1
Authority
EP
European Patent Office
Prior art keywords
methyl
group
cancer
amino
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16823908.5A
Other languages
German (de)
English (en)
Other versions
EP3323817A4 (fr
EP3323817B1 (fr
Inventor
Yan Zhu
Na Zhao
Xianxing SHANG
Yuandong Hu
Yong Peng
Hui Zhang
Bo Liu
Hong Luo
Yongxin Han
Ling Yang
Hongjiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of EP3323817A1 publication Critical patent/EP3323817A1/fr
Publication of EP3323817A4 publication Critical patent/EP3323817A4/fr
Application granted granted Critical
Publication of EP3323817B1 publication Critical patent/EP3323817B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present application relates to anilinopyrimidine derivatives as EGFR inhibitors, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same, and methods or uses for treating EGFR-mediated diseases using the same.
  • EGFR Epithelial Growth Factor Receptor
  • HER1 epithelial growth factor
  • ErbB-1 epithelial growth factor
  • ErbB-2 epithelial growth factor
  • HER3 epithelial growth factor
  • HER4 ErbB-4
  • EGFR is a transmembrane glycoprotein with a molecular weight of 170KDa, which belongs to a tyrosine kinase receptor.
  • EGFR is located on the surface of cell membranes and is activated by binding to ligands including EGF and TGF ⁇ . Upon being activated, EGFR undergoes a transition from a monomer to a dimer.
  • the dimer includes not only the binding of two identical receptor molecules (homodimerization) but also the binding of different members of the human EGF-associated receptor (HER) tyrosine kinase family (heterodimerization).
  • HER human EGF-associated receptor
  • EGFR can activate its intracellular kinase pathways after dimerization, resulting in the phosphorylation of key tyrosine residues in the intracellular domain and the stimulation to many intracellular signaling pathways involved in cell proliferation and survival.
  • EGFR is associated with tumor cell proliferation, angiogenesis, tumor invasion, metastasis and the inhibition of apoptosis.
  • Possible mechanisms include the followings: enhanced downstream signal transduction caused by the high expressions of EGFR; the sustained activation of EGFR caused by the increased expressions of mutant EGFR receptors or ligands; the enhanced effect of autocrine loops; the destruction of receptor downregulation mechanisms; and the activation of aberrant signaling pathways, etc.
  • Overexpressions of EGFR play an important role in the progression of malignant tumors. For example, overexpressions of EGFR have been found in gliocyte, kidney cancer, lung cancer, prostate cancer, pancreatic cancer, breast cancer and other tissues.
  • EGFR Aberrant expressions of EGFR and Erb-B2 play a crucial role in tumor transformation and growth.
  • NSCLC non-small cell lung cancer
  • EGFR is expressed in 50% of non-small cell lung cancer (NSCLC) cases and its expression is associated with poor prognosis.
  • NSCLC non-small cell lung cancer
  • the two factors allow EGFR and its family members to be major candidates of targeted therapy.
  • T790M mutation is a point mutation in exon 20 of EGFR, which leads to acquired resistance to the treatment with gefitinib or erlotinib.
  • a recent study shows that the combination of L858R and T790M mutations has a stronger affinity for ATP than L858R alone, and TKIs are ATP-competitive kinase inhibitors, and thereby resulting in a decreased binding rate between TKIs and kinase domains.
  • the present application provides a compound represented by Formula (I), or a pharmaceutically acceptable salt thereof: wherein:
  • the compounds of Formula (I) of the present application include the following compounds or pharmaceutically acceptable salts thereof:
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by Formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the pharmaceutical composition of the present application may further comprise one or more additional therapeutic agents.
  • the present application provides a method for treating an EGFR-mediated disease, comprising administering to a subject in need thereof a compound of Formula (I) of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
  • the present application provides use of a compound of Formula (I) of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for the treatment of an EGFR-mediated disease.
  • the EGFR-mediated disease is selected from diseases mediated by an EGFR-L858R activating mutation.
  • the EGFR-mediated disease is selected from diseases mediated by an EGFR-T790M activating mutation. In some embodiments, the EGFR-mediated disease is selected from diseases mediated by EGFR-L858R+EGFR-T790M double-activating mutations.
  • C m-n as used herein means that the moiety has m-n carbon atoms.
  • C 1-4 alkyl means that the alkyl has1-4 carbon atoms.
  • C 1-4 means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms.
  • halo or halogen refers to fluoro, chloro, bromo, or iodo.
  • cyano refers to -CN group.
  • alkyl refers to a straight or branched saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, which is attached to the rest of the molecule via a single bond.
  • alkyl include, but are not limited to, methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl or tert-butyl and the like.
  • alkoxy refers to an "-O-alkyl” group.
  • pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • a salt formed with an inorganic acid a salt formed with an organic acid, a salt formed with an acidic amino acid, and the like can be mentioned as a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt as used herein can be synthesized from a parent compound containing an acid radical or a base radical through a conventional chemical process.
  • the process for preparing such a salt comprises: reacting these compounds in the form of a free base with a stoichiometric appropriate acid in water or an organic solvent or a mixture of water and an organic solvent.
  • Some of the compounds of the present application may exist in a non-solvate form or a solvate form, including a hydrate form.
  • the solvate form is comparative to the non-solvate form, and both of them are contemplated by the present application.
  • Some of the compounds of the present application may exist in a polymorphic or amorphous form.
  • Some of the compounds of the present application may have an unsymmetrical carbon atom (an optical center) or double bond. Racemates, diastereoisomers, geometrical isomers and individual isomers are all included within the scope of the present application.
  • the compounds of the present application may have particular geometrical isomer or stereoisomer forms. Such compounds are all contemplated in the present application, including cis- and trans -isomers, (-)- and (+)-enantiomers, ( R )- and ( S )-enantiomers, diastereoisomers, ( D )-isomers, ( L )-isomers, and racemic mixtures thereof and other mixtures, such as a enantiomer or diastereoisomer-rich mixture. All such mixtures are included within the scope of the present application. Substituents such as alkyl may have additional unsymmetrical carbon atoms. Such isomers and mixtures thereof are all included within the scope of the present application.
  • Optically active ( R )- and ( S )-isomers and D - and L -isomers can be prepared by using chiral synthesis or chiral reagents, or other conventional technology. If one enantiomer of certain compound of the present application is desired, this enantiomer can be prepared by an asymmetric synthesis or a derivatization process with a chiral auxiliary, which comprises separating a mixture of diastereoisomers, and cleaving assistant groups to provide a desired pure enantiomer.
  • a diastereoisomer salt can be formed by the molecule and an appropriate optically active acid or base, and then the diastereoisomer is resolved by a fractional crystallization or chromatography as well-known in the art, thereby recovering a pure enantiomer.
  • the separation of an enantiomer and a diastereoisomer is generally achieved by a chromatography using a chiral stationary phase, or optionally combining with a chemical derivatization process ( e . g ., using an amine to produce a carbamate salt).
  • the compound of the present application may contain atomic isotopes at a non-natural ratio, on one or more atoms that constitute the compound.
  • atomic isotopes may be deuterium (D), tritium ( 3 H), iodine-125 ( 125 I), carbon-14 ( 14 C) and so on.
  • D deuterium
  • 3 H tritium
  • iodine-125 125 I
  • carbon-14 14 C
  • pharmaceutically acceptable carrier refers to those carriers which have no significant irritation to an organism and do not impair the bioactivity and property of the active compound.
  • pharmaceutically acceptable carrier refers to an inert substance which is administered with an active ingredient and is beneficial to the administration of the active ingredient, and includes but not limited to any of the following substances which are acceptable for use in humans or animals (e.g. livestocks) approved by the State Food and Drug Administration: glidants, sweetening agents, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersants, disintegrants, suspending agents, stabilizing agents, isotonic agents, solvents or emulsifying agents.
  • Non-limiting examples of the carriers comprise calcium carbonate, calcium phosphate, various sugars and starches, cellulose derivatives, gelatines, vegetable oil and polyethylene glycol and the like. Other information regarding the carriers may refer to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005 ), of which the contents are incorporated herein by reference.
  • excipient generally refers to a carrier, diluent and/or medium used to formulate an effective pharmaceutical composition.
  • the term "effective amount” or “therapeutically effective amount” refers to the amount of a medicament or agent which is nontoxic but sufficient to achieve the desired effect.
  • the "effective amount” for an active substance in the composition refers to the amount required to achieve the desired effect in combination with another active substance in the composition.
  • the determination of the effective amount varies from person to person and depends on the age and general condition of the receptor as well as the specific active substance. The effective amount in a specific case can be determined by a person skilled in the art through conventional tests.
  • active ingredient refers to a chemical entity which is useful for treating target disorders, diseases or conditions effectively.
  • patient or “subject” includes humans and animals, for example, mammals (such as primates, cattle, horses, pigs, dogs, cats, mice, rats, rabbits, goats, sheep and birds).
  • mammals such as primates, cattle, horses, pigs, dogs, cats, mice, rats, rabbits, goats, sheep and birds.
  • the present application provides a compound represented by Formula (I), or a pharmaceutically acceptable salt thereof: wherein:
  • the compounds of Formula (I) of the present application include the following compounds or pharmaceutically acceptable salts thereof:
  • the pharmaceutically acceptable salts of the compounds of Formula (I) of the present application include the following hydrochloride salts of the compounds:
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the pharmaceutical composition of the present application may further comprise one or more additional therapeutic agents.
  • the present application provides a method for treating an EGFR-mediated disease, comprising administering to a subject in need thereof a compound of Formula (I) of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
  • the present application provides use of a compound of Formula (I) of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for the treatment of an EGFR-mediated disease.
  • the EGFR-mediated disease is selected from diseases mediated by an EGFR-L858R activating mutation.
  • the EGFR-mediated disease is selected from diseases mediated by an EGFR-T790M activating mutation.
  • the EGFR-mediated disease is selected from diseases mediated by EGFR-L858R+EGFR-T790M double-activating mutations.
  • the EGFR-mediated disease is a cancer
  • the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, stomach cancer, lung cancer, hepatocellular cancer, stomach cancer, gastrointestinal stromal tumor, thyroid cancer, cholangiocarcinoma, endometrial cancer, kidney cancer, anaplastic large cell lymphoma, acute myeloid leukemia, multiple myeloma, melanoma, and mesothelioma;
  • the lung cancer may be selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma and squamous cell lung cancer.
  • the pharmaceutical composition of the present application can be prepared by combining a compound of the present application or a salt thereof with a suitable pharmaceutically acceptable carrier, and may be formulated into, for example, solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, pastes, emulsions, suspensions, solutions, suppositories, injections, inhalants, gels, microspheres, aerosols and the like.
  • Typical administration routes of the compound of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same include, but are not limited to, oral, rectal, transmucosal, or enteral administration, or topical, transdermal, inhaled, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, or intravenous administration.
  • the pharmaceutical composition of the present application can be manufactured through the well-known methods in the art, such as a conventional mixing method, dissolving method, granulation method, sugar-coated-pill method, grinding method, emulsification method, and freeze-drying method, etc.
  • the active compound can be mixed with the pharmaceutically acceptable carriers known in the art, to prepare the pharmaceutical composition.
  • the compounds of the present application can be formulated into tablets, pills, lozenges, sugar-coated tablets, capsules, liquid, gels, syrup, or suspensions and the like, for oral administration to patients.
  • the solid oral composition can be prepared by conventional mixing, filling or compressing method. For example, it can be obtained through the following method: the active compound is mixed with solid excipients; optionally the resulting mixture is ground, and other suitable excipients are added if needed; then the mixture is processed into granules, so that the core of tablets or sugar-coated tablets is obtained.
  • Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants, sweeteners and/or flavoring agents, etc., such as microcrystalline cellulose, glucose solutions, acacia mucilage, gelatin solutions, sucrose and/or starch pastes; talc, starch, magnesium stearate, calcium stearate and/or stearic acid; lactose, sucrose, starch, mannitol, sorbitol and/or dicalcium phosphate; silica; crosslinked sodium carboxymethylcellulose, pre-gelatinized starch, sodium starch glycolate, alginic acid, corn starch, potato starch, methyl cellulose, agar, carboxymethyl cellulose, and/or crosslinked polyvinylpyrrolidone, etc.
  • the core of the sugar-coated tablet can be coated through the well-known methods in general pharmaceutical practice, and enteric coating is particularly used.
  • the pharmaceutical composition is also suitable for parenteral administration, such as sterile solutions, suspensions or freeze-dried products in an adequate unit dose form.
  • the compound of Formula (I) as described herein or a pharmaceutically acceptable salt thereof can be administered by any suitable routes and methods, for example, by oral or parenteral (e.g., intravenous) administration.
  • Therapeutically effective amounts of the compound of Formula (I) are from about 0.0001 to 20 mg/Kg body weight per day, such as from 0.001 to 10 mg/Kg body weight per day.
  • the frequency of dosage of the compound of Formula (I) is determined by the needs of the individual patient and can be, for example, once or twice per day, or more times per day.
  • Administration can be intermittent, for example, with a period of several days during which a patient receives a daily dose of a compound of Formula (I), followed by a period of several days during which a patient does not receive a daily dose of the compound of Formula (I).
  • the compounds of the present application can be prepared by a variety of synthetic processes well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining the specific embodiments with other chemical synthetic processes, and equivalent alternatives known to a person skilled in the art. Specific embodiments include, but are not limited to, the examples of the present application.
  • the chemical reaction of a specific embodiment of the present application is carried out in a suitable solvent, and the solvent should be suitable for the chemical changes of the present application and the required reagents and materials thereof.
  • a person skilled in the art sometimes needs to modify or select a synthesis step or a reaction process on the basis of the present embodiments.
  • the chlorine atom on the pyrimidine ring of the compound of Formula (VI) is reacted with the amino group on the benzene ring of a compound of Formula (VII) to obtain a compound of Formula (VIII), which then is attached to a side chain R 4 to obtain a compound of Formula (IX).
  • the nitro group of the compound of Formula (IX) is reduced to an amino group, which then forms an amide bond with a compound of Formula (XI) to give a compound of Formula (I-a) as a final product.
  • a substitution reaction between the chlorine atom on the pyrimidine ring of the compound of Formula (XV) and the amino group on the benzene ring of the compound of Formula (VII) occurs to obtain a compound of Formula (XVI), which then is attached to a side chain R 4 to obtain a compound of Formula (XVII).
  • the nitro group of the compound of Formula (XVII) is reduced to an amino group, which then forms an amide bond with a compound of Formula (XI) to give a compound of Formula (I-b) as a final product.
  • the solvents used in the present application are commercially available and can be used without further purification. All operations involving moisture and/or oxygen sensitive experiments were conducted under nitrogen atmosphere in pre-dried glassware. Unless noted otherwise, all the materials were obtained from commercially available sources and used without further purification.
  • Column chromatography used in the present application was performed on silica gel (200-300 mesh) produced by Qingdao Haiyang Chemical CO., LTD. Thin layer chromatography was performed using precoated chromatography plates purchased from E. Merck (silica gel 60PF254, 0.25 mm). The instrument used for nuclear magnetic resonance spectroscopy analysis was Varian VNMRS-400 resonance spectrometer.
  • DMF means N,N-dimethylformamide
  • NMP means N-methylpyrrolidone
  • DCM dichloromethane
  • PE means petroleum ether
  • EA means ethyl acetate
  • MeOH means methanol
  • Pd 2 (dba) 3 means tris(dibenzylideneacetone)dipalladium
  • TsOH means p-toluenesulfonic acid
  • BINAP means ( ⁇ )-2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl.
  • the compounds are nominated manually or by the ChemDraw® software.
  • their names provided in the catalogs of the suppliers are used.
  • Example 1 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • Step 1 N 1 -(2-chloropyrimidin-4-yl)benzene-1,2-diamine
  • Step 2 1-(2-chloropyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one
  • N 1 -(2-chloropyrimidin-4-yl)phenyl-1,2-diamine (2.21 g, 10 mmol) was dissolved in DMF (15 mL), and carbonyldiimidazole (2.43 g, 15 mmol) was added thereto and the resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was poured into water (50 mL) and stirring was continued for 10 minutes. Then the resulting mixture was suction-filtered, and the filter cake was washed with water (30 mL * 3), and dried to give the title compound (2.23 g, 90%).
  • Step 3 1-(2-chloropyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 4 1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate
  • Step 5 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 6 1-(2-(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 7 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • Step 1 1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) - 1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate
  • Step 2 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(2-oxo -2,3-dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one by a method similar to those described in Steps 6 and 7 of Example 1.
  • N 1 -(2,5-dichloropyrimidin-4-yl)benzene-1,2-diamine 100 mg, 0.39 mmol was dissolved in ethyl acetate (5 mL), and diisopropylethylamine (151 mg, 1.17 mmol) was added thereto and cooled in an ice-water bath. Then triphosgene (71 mg, 0.24 mmol) was added in batches. The resulting mixture was allowed to naturally warm to room temperature, and stirring was continued for 1 hour. Saturated sodium bicarbonate solution (10 mL) was added, and stirring was continued for 10 minutes.
  • Step 3 1-(2,5-dichloropyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 4 1-(5-chloro-2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) -3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 5 1-(5-chloro-2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 6 1-(2-(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-5-chloropyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 7 N -(5-(5-chloro-4-(3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazol-1 -yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • Step 1 1-(5-chloro-2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) -1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 2 1-(5-chloro-2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 N -(5-(5-chloro-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1 -yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • Step 1 2-chloro- N -(2-methoxyphenyl)pyrimidin-4-amine
  • Step 3 3-(2-chloropyrimidin-4-yl)benzo[ d ]oxazol-2(3 H )-one
  • Step 4 3 - (2 - (4 -fluoro -2-methoxy- 5-nitrophenylamino)pyrimidin-4-yl)benzo[ d ] oxazol-2(3 H )-one p-toluenesulfonate
  • Step 5 3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)benzo[ d ]oxazol-2(3H)-one
  • Step 6 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(2 -oxobenzo[ d ]oxazol-3(2 H )-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • Step 1 1-(2-(4-((2-hydroxyethyl)(methyl)amino)-2-methoxy-5-nitrophenylarmino) pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 2 N -(2-((2-hydroxyethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3 -dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide
  • the title compound was prepared from 1-(2-(4-((2-hydroxyethyl)(methyl)amino) -2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one by a method similar to those described in Steps 6 and 7 of Example 1.
  • Example 7 (E)- N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4 -(3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)-4 -methoxybut-2-enamide
  • the title compound was prepared from 1-(2-(5-amino-4-((2-(dimethylamino)ethyl) (methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol -2(3 H )-one and ( E )-4-methoxybut-2-enoyl chloride by a method similar to that described in Step 7 of Example 1.
  • Example 8 N -(4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[ d ]midazol-1-yl) pyrimidin-2-ylamino)-2-morpholinophenyl)acrylamide
  • Step 1 1-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate and morpholine by a method similar to that described in Step 5 of Example 1.
  • Step 2 N -(4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[ d ]imidazol-1-yl) pyrimidin-2-ylamino)-2-morpholinophenyl)acrylamide
  • Step 2 1-(2-chloropyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate
  • the title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.
  • Step 4 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate and diisopropylethylamine by a method similar to that described in Step 5 of Example 1.
  • Step 5 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(5-methyl-2-oxo-2,3-dihydrobenzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-methyl-1 H -benzo[ d ]imidazol-2(3 H ) -one by a method similar to those described in Steps 6 and 7 of Example 1.
  • Step 2 1-(2-chloropyrimidin-4-yl)-5-fluoro-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 1-(2-chloropyrimidin-4-yl)-5-fluoro-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 4 5-fluoro-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate
  • the title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-fluoro-3-methyl -1 H -benzo[ d ]imidazol-2(3 H )-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1, and was directly used in the next reaction step.
  • Step 5 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-fluoro-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 5-fluoro-1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate by a method similar to that described in Step 5 of Example 1.
  • Step 6 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(5-fluoro-3 -methyl-2-oxo-2,3 -dihydrobenzo [ d ]imidazol-1-yl)pyrimidin-2-ylamino)-4-methoxyphenyl) acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-fluoro-3-methyl-1 H -benzo[ d ] imidazol-2(3 H )-one by a method similar to those described in Steps 6 and 7 of Example 1.
  • Step 1 5-fluoro-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3H)-one p-toluenesulfonate
  • Step 2 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-fluoro-1H-benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 5-fluoro-1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate by a method similar to that described in Step 5 of Example 1.
  • Step 3 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(5-fluoro-2-oxo -2,3-dihydrobenzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-fluoro-1 H -benzo[ d ]imidazol-2(3 H )-one by a method similar to those described in Steps 6 and 7 of Example 1.
  • Step 1 tert-butyl 2-((5-methoxy-4-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[ d ]imidazol -1-yl)pyrimidin-2-ylamino)-2-nitrophenyl)(methyl)amino)ethyl(methyl)carbamate
  • the title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one p-toluenesulfonate and tert-butyl 2-(methylamino)ethylcarbamate by a method similar to that described in Step 5 of Example 1.
  • Step 2 tert-butyl 2-((2-acrylamido-5-methoxy-4-(4-(3-methyl-2-oxo-2,3-dihydrobenzo [ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)(methyl)amino)ethyl(methyl) carbamate
  • the title compound was prepared from tert-butyl 2-((5-methoxy-4-(4-(3-methyl-2 -oxo-2,3-dihydrobenzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)-2-nitrophenyl)(methyl)amino) ethyl(methyl) carbamate by a method similar to those described in Steps 6 and 7 of Example 1.
  • Step 3 N -(4-methoxy-2-(methyl(2-(methylamino)ethyl)amino)-5-(4-(3-methyl-2-oxo -2,3-dihydrobenzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
  • Acetyl chloride (0.3 mL, 1.7 mmol) was slowly added dropwise to anhydrous methanol (3 mL) cooled with an external ice-water bath and stirring was continued for 1 hour.
  • tert-butyl 2-((2-acrylamido-5-methoxy-4-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[ d ]imidazol-1-yl) pyrimidin-2-ylamino)phenyl)(methyl)amino)ethyl(methyl)carbamate (100 mg, 0.166 mmol) was dispersed in anhydrous methanol (2 mL) and then added into the above solution of hydrogen chloride in methanol.
  • Example 13 N -(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide
  • Example 14 N-(5-(4-(5-chloro-3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazole -1-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • Step 1 4-chloro -N 1 -(2-chloropyrimidin-4-yl)benzene-1,2-diamine
  • Step 2 5-chloro-1-(2-chloropyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 5-chloro-1-(2-chloropyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol -2(3 H )-one
  • Step 4 5-chloro-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 5-chloro-1-(2-chloropyrimidin-4-yl)-3 -methyl-1 H -benzo[d]imidazol-2(3 H )-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.
  • Step 5 5-chloro-1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[ d ]imidazol-2(3 H )-one
  • Step 6 1-(2-(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-chloro-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 7 N-(5-(4-(5-chloro-3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazole -1-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(5-amino-4-((2-(dimethylamino)ethyl) (methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-chloro-3-methyl-1 H -benzo[ d ] imidazol-2(3 H )-one by a method similar to that described in Step 7 of Example 1.
  • Example 15 N-(5-(4-(5-bromo-3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazole -1-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • Step 1 4-bromo- N 1 -(2-chloropyrimidin-4-yl)benzene-1,2-diamine
  • Step 2 5-bromo-1-(2-chloropyrimidin-4-yl)-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 3 5-bromo-1-(2-chloropyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol -2(3 H )-one
  • Step 4 5-bromo-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • the title compound was prepared from 5-bromo-1-(2-chloropyrimidin-4-yl)-3 -methyl-1 H -benzo[ d ]imidazol-2(3 H )-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.
  • Step 5 5-bromo-1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1 H -benzo[ d ]imidazol-2(3 H )-one
  • Step 6 1-(2-(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-bromo-3-methyl-1 H -benzo[ d ]imidazol-2(3H)-one
  • Step 7 N-(5-(4-(5-bromo-3-methyl-2-oxo-2,3-dihydro-1 H -benzo[ d ]imidazole -1-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
  • the title compound was prepared from 1-(2-(5-amino-4-((2-(dimethylamino)ethyl) (methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-bromo-3-methyl-1 H -benzo[ d ] imidazol-2(3 H )-one by a method similar to that described in Step 7 of Example 1.
  • EGFR or EGFR (T790M, L858R) kinase was expressed and purified through an insect cell expression system, or purchased as commercially available products.
  • a platform for testing the activities of EGFR or EGFR (T790M, L858R) kinase was established based on the Homogeneous Time-Resolved Fluorescence (HTRF) method provided by Cisbio Inc., and was used for determining the activities of compounds.
  • the compounds were diluted at a 10-fold gradient with 100% DMSO with a starting concentration of 1 ⁇ M. 4 ⁇ l of each concentration was taken and added to 96 ⁇ l of reaction buffer (50 mM HEPES (pH 7.0), 0.02% NaN 3 , 0.01% BSA, 0.1 mM Orthovanadate, 5 mM MgCl 2 , 50 nM SEB, 1 mM DTT).
  • Human non-small cell lung cancer cells NCI-H1975 were cultured in RPIM-1640 culture medium supplemented with 10% fetal bovine serum and 1% penicillin-plus-streptomycin in a cell incubator (37°C, 5% CO 2 ). The cells were seeded in a 96-well plate at a density of 2,000 cells per well (volume: 195 ⁇ l) and cultured overnight. On the next day, the compounds were added. In particular, the compounds were diluted at a 3-fold gradient with a starting concentration of 10 mM. 4 ⁇ l of each concentration was taken and added into 96 ⁇ l of culture medium.
  • Human skin squamous carcinoma cell line A431 was cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-plus-streptomycin in a cell incubator (37°C, 5% CO 2 ). In the tests of the compounds, the bottom substrate was at a concentration of 0.6%. Cells were re-suspended with 0.3% low-melting-point agar, and then seeded in a 96-well plate at a density of 2,000 cells per well (100 ⁇ l). The compounds were diluted at a 3-fold gradient with a starting concentration of 10 mM.
  • Example 1 Biological activity Compound Enzymatic activity (IC 50 nM) Cell viability (IC 50 nM) EGFR(WT) EGFR-L858R/T 790M(DM) WT/DM A431 NCI-H1975 AZD9291 19.45 2.04 9.5 53.54 9.08 Example 1 9.07 0.72 12.6 22.49 2.76 Example 2 2.59 0.43 6.0 NT 0.96 Example 3 196.5 4.61 42.6 NT NT Example 4 20.61 1.15 17.9 NT 2.87 Example 5 44.86 2.27 19.8 NT 16.99 Example 7 163.6 4.12 39.7 NT NT Example 9 3.93 0.64 6.1 NT NT Example 10 10.66 0.58 18.4 NT 1.46 Example 11 2.79 0.67 4.2 NT 3.70 Example 12 5.26 0.50 10.5 NT 3.17 Example 14 NT NT NT 537.7 4.56 Example 15 NT NT NT 833.8 6.83 NT: not tested; AZD9291 was prepared according to the description in Example 28 in WO
  • the compounds of the present application showed good inhibitory effect on EGFR, especially the EGFR-L858R/T790M double mutant.
  • the WT/DM data showed that the compounds of the present application had desired selectivity.
  • the compounds of the present application showed good inhibitory effect on human non-small cell lung cancer NCI-H1975 and human skin squamous carcinoma cell line A431.
  • Healthy adult male rats were subjected to single-dose intragastric administration of the test compounds at a dose of 10 mg/kg with 20% sulfobutyl ether- ⁇ -cyclodextrin as an excipient. Before the experiment, the animals were fasted overnight, and the fasting time last from 10 hrs prior to the administration to 4 hrs after the administration. At 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hrs after the intragastric administration, blood sampling was conducted. Approximately 0.3 mL of whole blood was collected from retro-orbital venous sinus, and placed into tubes that contained heparin as an anticoagulant. The samples were centrifuged at 4°C and 4000 rpm for 5 min.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16823908.5A 2015-07-16 2016-07-15 Dérivés d'aniline pyrimidine et leurs utilisations Active EP3323817B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510419018 2015-07-16
PCT/CN2016/090149 WO2017008761A1 (fr) 2015-07-16 2016-07-15 Dérivés d'aniline pyrimidine et leurs utilisations

Publications (3)

Publication Number Publication Date
EP3323817A1 true EP3323817A1 (fr) 2018-05-23
EP3323817A4 EP3323817A4 (fr) 2019-04-10
EP3323817B1 EP3323817B1 (fr) 2022-10-19

Family

ID=57756722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16823908.5A Active EP3323817B1 (fr) 2015-07-16 2016-07-15 Dérivés d'aniline pyrimidine et leurs utilisations

Country Status (11)

Country Link
US (1) US10329277B2 (fr)
EP (1) EP3323817B1 (fr)
JP (1) JP6970081B2 (fr)
KR (1) KR102666414B1 (fr)
CN (1) CN107835811B (fr)
AU (1) AU2016292450B2 (fr)
CA (1) CA2992317A1 (fr)
HK (1) HK1250164A1 (fr)
RU (1) RU2734849C2 (fr)
TW (1) TWI739753B (fr)
WO (1) WO2017008761A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3998268A4 (fr) * 2019-07-04 2023-06-21 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Composé pour inhiber la kinase egfr et son procédé de préparation et son utilisation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3205650B1 (fr) * 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Inhibiteur d'egfr, et préparation et application associées
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
EP3943491A4 (fr) * 2019-03-19 2022-11-23 Voronoi Inc. Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
AU3704101A (en) * 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
CA2778265A1 (fr) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines utilisees comme nouvel echafaudage pour l'inhibition des kinases a cibles multiples
CA2780031A1 (fr) * 2009-11-12 2011-05-19 Selvita S.A. Compose, procede pour sa preparation, composition pharmaceutique, utilisation d'un compose, procede de modulation ou de regulation de serine/threonine kinases et agent modulateur de serine/threonine kinases
WO2011140338A1 (fr) * 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Composés modulant l'activité des récepteurs egfr et méthodes pour traiter ou prévenir des troubles à l'aide de ceux-ci
ES2900230T3 (es) * 2011-07-27 2022-03-16 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3998268A4 (fr) * 2019-07-04 2023-06-21 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Composé pour inhiber la kinase egfr et son procédé de préparation et son utilisation
US11993598B2 (en) 2019-07-04 2024-05-28 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compounds for inhibiting EGFR kinase, preparation methods and uses thereof

Also Published As

Publication number Publication date
TWI739753B (zh) 2021-09-21
CN107835811B (zh) 2019-11-08
RU2734849C2 (ru) 2020-10-23
KR20180030190A (ko) 2018-03-21
KR102666414B1 (ko) 2024-05-17
RU2018102963A (ru) 2019-08-16
RU2018102963A3 (fr) 2019-12-24
WO2017008761A1 (fr) 2017-01-19
US20180208581A1 (en) 2018-07-26
JP2018520190A (ja) 2018-07-26
AU2016292450B2 (en) 2021-03-25
JP6970081B2 (ja) 2021-11-24
EP3323817A4 (fr) 2019-04-10
US10329277B2 (en) 2019-06-25
TW201703768A (zh) 2017-02-01
EP3323817B1 (fr) 2022-10-19
CN107835811A (zh) 2018-03-23
AU2016292450A1 (en) 2018-02-15
CA2992317A1 (fr) 2017-01-19
HK1250164A1 (zh) 2018-11-30

Similar Documents

Publication Publication Date Title
EP3323817B1 (fr) Dérivés d'aniline pyrimidine et leurs utilisations
EP1652847B1 (fr) Dérivés de quinoline et quinazoline pour le traitement de tumeurs
US9242991B2 (en) Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
EP2883875A1 (fr) Dérivé de n2,n4-bis(4-(pipérazine-1-yl)phényl)pirimidine-2,4-diamine ou sel pharmaceutiquement acceptable de celui-ci, et composition contenant celle-ci en tant que substance active pour prévenir ou traiter un cancer
JP2015524448A (ja) アルキニルへテロ芳香環化合物及びその応用
EP3037424A1 (fr) Nouveau composé substitué par une quinoline
US20200361908A1 (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
EP3476846A1 (fr) Nouveau dérivé hétérocyclique et son utilisation
EP3865487A1 (fr) Composés de dioxane-quinazoline ou dioxane-quinoléine liés à un cycle aromatique, compositions et utilisation associées
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
US20230133169A1 (en) Egfr inhibitor, composition, and method for preparation thereof
CN114380806B (zh) 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
KR101514162B1 (ko) 옥사졸로[5,4-b]피리딘-5-일 화합물 및 암의 치료를 위한 그의 용도
CN111484484B (zh) 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
JP2018087173A (ja) 悪性脳腫瘍治療薬
CN113354630A (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
CN117357650A (zh) 包含sos1抑制剂的药物组合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5377 20060101ALI20190301BHEP

Ipc: C07D 403/04 20060101AFI20190301BHEP

Ipc: A61P 35/00 20060101ALI20190301BHEP

Ipc: A61K 31/506 20060101ALI20190301BHEP

Ipc: A61P 35/02 20060101ALI20190301BHEP

Ipc: C07D 413/04 20060101ALI20190301BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220517

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENTAURUS BIOPHARMA CO., LTD.

Owner name: LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO.,LTD

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016075778

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1525489

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221115

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20221019

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1525489

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230220

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230119

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230219

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230120

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016075778

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

26N No opposition filed

Effective date: 20230720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230715

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221019

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230715

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240627

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230715

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240621

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240625

Year of fee payment: 9